DNA topoisomerase I and II in cancer chemotherapy : update and perspectivesPOMMIER, Y.Cancer chemotherapy and pharmacology. 1993, Vol 32, Num 2, pp 103-108, issn 0344-5704Conference Paper

LE METHOTREXATEPOMMIER Y; LOKIEC F.1981; REV. PRAT.; ISSN 0035-2640; FRA; DA. 1981; VOL. 31; NO 43; PP. 3083-3089; ABS. ENG; BIBL. 7 REF.Article

INHIBITORS OF POLY-(ADENOSINE DIPHOSPHORIBOSE) SYNTHESIS SLOW THE RESEALING RATE OF X-RAY-INDUCED DNA STRAND BREAKSZWELLING LA; KERRIGAN D; POMMIER Y et al.1982; BIOCHEM. BIOPHYS. RES. COMMUN.; ISSN 0006-291X; USA; DA. 1982; VOL. 104; NO 3; PP. 897-902; BIBL. 26 REF.Article

TOXICITE DU METHOTREXATE A FORTE DOSE. DONNEES PHARMACOCINETIQUESPOMMIER Y; LOKIEC F; ZITTOUN R et al.1982; NOUV. PRESSE MED.; ISSN 0301-1518; FRA; DA. 1982; VOL. 11; NO 7; PP. 524; BIBL. 3 REF.Article

Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNAFESEN, M; POMMIER, Y.The Journal of biological chemistry (Print). 1989, Vol 264, Num 19, pp 11354-11359, issn 0021-9258, 6 p.Article

SPONDYLODISCITES. DIAGNOSTIC ETIOLOGIQUE EN DEHORS DE L'URGENCE NEURO-CHIRURGICALE.POMMIER Y; HERON JF; L'HIRONDEL JL et al.1977; J. MED. CAEN; FR.; DA. 1977; VOL. 12; NO 2; PP. 49-53; BIBL. 20 REF.Article

Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the nci anticancer drug screen : Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathwaysNIEVES-NEIRA, W; POMMIER, Y.International journal of cancer. 1999, Vol 82, Num 3, pp 396-404, issn 0020-7136Article

Topoisomerase I alteration in a camptothecin-resistant cell line derivated from Chinese hamster DC3F cells in cultureTANIZAWA, A; POMMIER, Y.Cancer research (Baltimore). 1992, Vol 52, Num 7, pp 1848-1854, issn 0008-5472Conference Paper

Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteasesSHIMIZU, T; POMMIER, Y.Leukemia. 1997, Vol 11, Num 8, pp 1238-1244, issn 0887-6924Article

La résistance pléiotropique liéee aux topo-isomérases = Pleiotropic resistance related to topoisomerasesRIOU, J. F; POMMIER, Y.Bulletin du cancer. Supplément. 1994, Vol 81, Num 2, pp 62s-68s, issn 0927-3085Conference Paper

HIGH-DOSE CYTARABINE IN ACUTE LEUKEMIA: TOXICITY AND PHARMACOKINETICS = CYTARABINE A HAUTE DOSE DANS LES LEUCEMIES AIGUES: TOXICITE ET PHARMACOCINETIQUEPOMMIER Y; POCHAT L; MARIE JP et al.1983; CANCER TREATMENT REPORTS; ISSN 0361-5960; USA; DA. 1983; VOL. 67; NO 4; PP. 371-373; ABS. ENG; BIBL. 13 REF.; GRAPHArticle

EFFECTS OF SOME ALPHA -ADRENOCEPTOR AGONISTS AND ANTAGONISTS ON THE GUINEA-PIG ILEUMANDREJAK M; POMMIER Y; MOUILLE P et al.1980; NAUNYN-SCHMIEDEBERG ARCH. PHARMACOL.; ISSN 0369-5565; DEU; DA. 1980; VOL. 314; NO 1; PP. 83-87; BIBL. 24 REF.Article

Design and discovery of HIV-1 integrase inhibitorsNEAMATI, N; SUNDER, S; POMMIER, Y et al.Drug discovery today. 1997, Vol 2, Num 11, pp 487-498, issn 1359-6446Article

DNA recombinase activity of eukaryotic DNA topoisomerase I ; effects of camptothecin and other inhibitorsPOMMIER, Y; JENKINS, J; KOHLHAGEN, G et al.Mutation research. DNA repair. 1995, Vol 337, Num 2, pp 135-145, issn 0921-8777Article

Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatmentSOLARY, E; BERTRAND, R; POMMIER, Y et al.Leukemia. 1994, Vol 8, Num 5, pp 792-797, issn 0887-6924Article

Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothetinTANIZAWA, A; KOHN, K. W; POMMIER, Y et al.Nucleic acids research. 1993, Vol 21, Num 22, pp 5157-5166, issn 0305-1048Article

FORMATION AND RESEALING OF INTERCALATOR-INDUCED DNA STRAND BREAKS IN PERMEABILIZED L1210 CELLS WITHOUT THE STIMULATED SYNTHESIS OF POLY(ADP-RIBOSE)ZWELLING LA; KERRIGAN D; POMMIER Y et al.1982; J. BIOL. CHEM.; ISSN 0021-9258; USA; DA. 1982; VOL. 257; NO 15; PP. 8957-8963; BIBL. 42 REF.Article

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trialsTANIZAWA, A; FUJIMORI, A; FUJIMORI, Y et al.Journal of the National Cancer Institute. 1994, Vol 86, Num 11, pp 836-842, issn 0027-8874Article

Le rôle de l'apoptose dans la genèse et le traitement du cancer = Apoptosis function in oncogenesis and cancer treatmentSOLARY, E; BERTRAND, R; POMMIER, Y et al.MS. Médecine sciences. 1993, Vol 9, Num 6-7, pp 667-675, issn 0767-0974Article

Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecinJAXEL, C; KOHN, K. W; POMMIER, Y et al.Nucleic acids research. 1988, Vol 16, Num 23, pp 11157-11170, issn 0305-1048Article

Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitorsBERTRAND, R; SOLARY, E; JENKINS, J et al.Experimental cell research. 1993, Vol 207, Num 2, pp 388-397, issn 0014-4827Article

Cell death induced by topoisomerase inhibitors : role of calcium in mammalian cellsBERTRAND, R; KERRIGAN, D; SARANG, M et al.Biochemical pharmacology. 1991, Vol 42, Num 1, pp 77-85, issn 0006-2952Article

Kinetics of indium-oxime labelled red cells in haemolytic anaemiasNAJEAN, Y; POMMIER, Y; DESCHRYVER, F et al.European journal of nuclear medicine. 1986, Vol 12, Num 8, pp 379-380, issn 0340-6997Article

LES SURVIES TRES PROLONGEES DE LEUCEMIE MYELOIDE CHRONIQUE. REVUE DE LA LITTERATURE AVEC ETUDE DES FACTEURS PRONOSTIQUES, A PROPOS D'UNE OBSERVATION D'UNE DUREE DE 18 MOIS ET DEMIDEBRAY J; POMMIER Y; AUDEBERT AA et al.1980; SEM. HOP.; FRA; DA. 1980; VOL. 56; NO 7-8; PP. 309-313; ABS. ENG; BIBL. 35 REF.Article

Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecinsPOMMIER, Y.Seminars in oncology. 1996, Vol 23, Num 1, pp 3-10, issn 0093-7754, SUP3Conference Paper